Immune Expression and Inhibition of Heat Shock Protein 90 in Uveal Melanoma

Purpose: To examine the immunohistochemical profile of heat shock protein 90 (Hsp90) in uveal melanoma and the cytotoxicity of an Hsp90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), in uveal melanoma cell lines. Experimental Design: Hsp90 expression was determined by immunohistochemistry in 44 paraffin-embedded sections of primary human uveal melanoma and in five uveal melanoma cell lines (92.1, OCM-1, MKT-BR, SP6.5, and UW-1). Sulforhodamine B–based proliferation assay was used to compare uveal melanoma cell growth with a range of concentrations of 17-AAG. Changes in cell migration, invasion, cell cycle fractions, and apoptotic activity were also evaluated. Expression of intracellular proteins was determined by Western blot analysis after 17-AAG exposure. Results: Immunohistochemical expression of Hsp90 was identified in 68% of the paraffin-embedded sections and significantly associated with largest tumor dimension (P = 0.03). 17-AAG significantly reduced the proliferation rates of uveal melanoma cell lines, with concentrations of 100 to 0.1 μmol/L. 17-AAG also significantly reduced the migratory and invasive capabilities of uveal melanoma cell lines. Cell cycle analysis showed that 17-AAG induced accumulations of cells in G1. Caspase-3 protease activity analysis, a marker for apoptosis, showed a significant increase after drug exposure. The cytotoxic effect of 17-AAG was associated with decreased levels of phosphorylated Akt and cyclin-dependent kinase 4. Conclusions: The immunohistochemical expression of Hsp90 in uveal melanoma indicates worse prognosis. To the best of our knowledge, this is the first report showing the inhibitory effect on uveal melanoma cells using 17-AAG to target Hsp90. Therefore, Hsp90 may be used as a potential target for treatment of patients with uveal melanoma.

[1]  Yuval Kluger,et al.  High HSP90 expression is associated with decreased survival in breast cancer. , 2007, Cancer research.

[2]  S. Larson,et al.  Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer , 2007, Clinical Cancer Research.

[3]  D. Faingold,et al.  Expression and migratory analysis of 5 human uveal melanoma cell lines for CXCL12, CXCL8, CXCL1, and HGF , 2007, Journal of carcinogenesis.

[4]  C. Garrido,et al.  Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy , 2007, Journal of leukocyte biology.

[5]  S. Mandrekar,et al.  A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer , 2006, Clinical Cancer Research.

[6]  K. Kitagawa,et al.  17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation , 2006, Oncogene.

[7]  F. Bucchieri,et al.  Expression of Heat Shock Proteins HSP10, HSP27, HSP60, HSP70, and HSP90 in Urothelial Carcinoma of Urinary Bladder , 2006 .

[8]  L. Medeiros,et al.  Inhibition of Heat Shock Protein 90 Function by 17-Allylamino-17-Demethoxy-Geldanamycin in Hodgkin's Lymphoma Cells Down-Regulates Akt Kinase, Dephosphorylates Extracellular Signal–Regulated Kinase, and Induces Cell Cycle Arrest and Cell Death , 2006, Clinical Cancer Research.

[9]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[10]  M. Burnier,et al.  Immunohistochemical expression of phospho-Akt in uveal melanoma , 2005, Melanoma research.

[11]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Sloan,et al.  Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Hong Zhang,et al.  Hsp90 Activation and Cell Cycle Regulation , 2004, Cell cycle.

[14]  T. Isobe,et al.  IC101 Induces Apoptosis by Akt Dephosphorylation via an Inhibition of Heat Shock Protein 90-ATP Binding Activity Accompanied by Preventing the Interaction with Akt in L1210 Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[15]  B. Eustace,et al.  Extracellular Roles for the Molecular Chaperone, HSP90 , 2004, Cell cycle.

[16]  M. Burnier,et al.  Pathological and prognostic features of uveal melanomas. , 2004, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[17]  J. Niederkorn,et al.  Resistance and susceptibility of human uveal melanoma cells to TRAIL-induced apoptosis. , 2004, Archives of ophthalmology.

[18]  Kou-Juey Wu,et al.  Direct Activation of HSP90A Transcription by c-Myc Contributes to c-Myc-induced Transformation* , 2004, Journal of Biological Chemistry.

[19]  E. Sausville,et al.  17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models , 2004, Anti-cancer drugs.

[20]  W. Stolz,et al.  Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases , 2004, Experimental dermatology.

[21]  Xiuying Xiao,et al.  Significance of expression of heat shock protein90α in human gastric cancer , 2003 .

[22]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[23]  L. Neckers,et al.  Cancer: The rules of attraction , 2003, Nature.

[24]  J. Keunen,et al.  Heat shock protein expression in the eye and in uveal melanoma. , 2003, Investigative ophthalmology & visual science.

[25]  A. Olshen,et al.  Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. , 2003, Cancer research.

[26]  T. Şimşek,et al.  Expression of heat‐shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[27]  J. Marshall,et al.  Cell Proliferation Profile of Five Human Uveal Melanoma Cell Lines of Different Metastatic Potential , 2002, Pathobiology.

[28]  I. Rennie,et al.  Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1α and TGF-β , 2002 .

[29]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[30]  P. Workman,et al.  HSP90 as a new therapeutic target for cancer therapy: the story unfolds , 2002, Expert opinion on biological therapy.

[31]  P. Workman,et al.  Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. , 2001, Cancer research.

[32]  S. Srinivasula,et al.  Negative regulation of cytochrome c‐mediated oligomerization of Apaf‐1 and activation of procaspase‐9 by heat shock protein 90 , 2000, The EMBO journal.

[33]  Philippe Daelemans,et al.  Expression des protéines de choc thermique dans les tumeurs des glandes salivaires: Etude immunohistochimique des HSP27, HSP70, HSP90 et HSP110 : à propos de 50 cas , 2000 .

[34]  J. Buchner,et al.  Hsp90 & Co. - a holding for folding. , 1999, Trends in biochemical sciences.

[35]  S. Hsu,et al.  Abundance of heat shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin's disease. , 1998, Cancer research.

[36]  N. Rosen,et al.  Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway* , 1998, The Journal of Biological Chemistry.

[37]  H. Stein,et al.  Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma , 1998, The British journal of ophthalmology.

[38]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[39]  Z. Naito,et al.  Expression and Roles of Heat Shock Proteins in Human Breast Cancer , 1996, Japanese journal of cancer research : Gann.

[40]  J. Harper,et al.  Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. , 1996, Genes & development.

[41]  S Detre,et al.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.

[42]  E. Danen,et al.  Establishment and characterization of an uveal‐melanoma cell line , 1995, International journal of cancer.

[43]  D. Albert,et al.  Establishment of cell lines of uveal melanoma. Methodology and characteristics. , 1984, Investigative ophthalmology & visual science.

[44]  J. Gamel,et al.  Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. , 1983, American journal of ophthalmology.

[45]  H. V. van Peperzeel,et al.  Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. , 1982, Human pathology.

[46]  Y. Sekido,et al.  Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .

[47]  Justis P. Ehlers,et al.  Molecular Pathobiology of Uveal Melanoma , 2006, International ophthalmology clinics.

[48]  A. Bedikian.  Metastatic Uveal Melanoma Therapy: Current Options , 2006, International ophthalmology clinics.

[49]  I. Konishi,et al.  Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. , 1998, Cancer detection and prevention.

[50]  R. Glynn,et al.  Epidemiologic aspects of uveal melanoma. , 1988, Survey of ophthalmology.